Repros Therapeutics, Inc. (RPRX) Reports Q2 Loss of $0.30
Repros Therapeutics, Inc. (NASDAQ: RPRX) reported Q2 EPS of ($0.30), versus ($0.20) reported last year. Revenue for the quarter came in at $1 thousand, versus $53 thousand reported last year.